Antibody drug conjugates (ADCs) have emerged as a new modality of biotherapeutics that offer high potential for targeted cancer treatment. An ADC is typically produced by chemically linking small-molecule cytotoxins (drugs) with a cancer-specific monoclonal antibody. As a result, an ADC exhibits additional heterogeneity compared to the corresponding monoclonal antibody. The level of heterogeneity for an ADC also depends on the conjugation chemistry and type of cytotoxin used. It is important to characterize the heterogeneity of an ADC to understand both process consistency and product stability.

In this webinar, Dr. April Xu (Senior Principal Scientist at Pfizer) will discuss the analytical challenges for characterization of ADCs. She will also describe various methods for ADC analysis by liquid chromatography and mass spectrometry.

What you will learn in this webinar:
• The analytical challenges encountered in analysis of antibodydrug conjugates
• Various methods for measuring quality attributes for ADCs
• Recent advances in ADC characterizations by LC-MS

Speaker:
Dr. April Xu
Senior Principal Scientist
Pfizer Biopharmaceutical Science

Original Broadcast Date: September 23rd, 2015

свернуть